61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

  • Pharma
  • May 17, 2025
  • 22 views
Fire disrupts production at GSK Pharma’s contract manufacturing site

GlaxoSmithKline Pharmaceuticals (GSK Pharma) on Friday informed the stock exchanges that a fire had occurred at one of its contract manufacturing facilities, causing a temporary disruption in production at the…

  • Pharma
  • May 16, 2025
  • 103 views
Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and Germany may rattle multinational pharmaceutical giants, but it…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fire disrupts production at GSK Pharma’s contract manufacturing site

Fire disrupts production at GSK Pharma’s contract manufacturing site

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here